Platelet activating factor

Platelet activating factor is a lipid of Glycerophospholipids (GP) class. Platelet activating factor is associated with abnormalities such as Atherosclerosis, Acute cholecystitis without calculus, Cholecystitis, Colitis and Cholecystitis, Acute. The involved functions are known as Cell Survival, Metabolic Inhibition, lipid oxidation, Apoptosis and Oxidation. Platelet activating factor often locates in soluble, Cellular Membrane, Smooth muscle (tissue), Intima and Tissue specimen. The associated genes with Platelet activating factor are apolipoprotein A-I Milano, Homologous Gene, TSPO gene, HBEGF gene and SLC33A1 gene. The related lipids are Hydroxycholesterols, Liposomes, 25-hydroxycholesterol, Lysophosphatidylcholines and Lipopolysaccharides. The related experimental models are Knock-out, Mouse Model and Transgenic Model.

Cross Reference

Introduction

To understand associated biological information of Platelet activating factor, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with Platelet activating factor?

Platelet activating factor is suspected in Ischemia, Pleurisy, Atherosclerosis, Inflammatory disorder, Retinal Diseases, Diabetes and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with Platelet activating factor

MeSH term MeSH ID Detail
Purpura, Thrombotic Thrombocytopenic D011697 6 associated lipids
Platelet Storage Pool Deficiency D010981 3 associated lipids
Thrombophilia D019851 6 associated lipids
Hepatitis B, Chronic D019694 4 associated lipids
Respiratory Syncytial Virus Infections D018357 10 associated lipids
Dementia, Multi-Infarct D015161 2 associated lipids
Leukocyte-Adhesion Deficiency Syndrome D018370 1 associated lipids
Neoplasms, Germ Cell and Embryonal D009373 4 associated lipids
Bronchopulmonary Sequestration D001998 3 associated lipids
Colitis, Ischemic D017091 3 associated lipids
Per page 10 20 50 100 | Total 288

PubChem Associated disorders and diseases

What pathways are associated with Platelet activating factor

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with Platelet activating factor?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with Platelet activating factor?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with Platelet activating factor?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with Platelet activating factor?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with Platelet activating factor?

Knock-out

Knock-out are used in the study 'A cardioprotective role for platelet-activating factor through NOS-dependent S-nitrosylation.' (Leary PJ et al., 2008).

Mouse Model

Mouse Model are used in the study 'A regulatory role of LPCAT1 in the synthesis of inflammatory lipids, PAF and LPC, in the retina of diabetic mice.' (Cheng L et al., 2009).

Transgenic Model

Transgenic Model are used in the study 'Heterogeneity in the sn-1 carbon chain of platelet-activating factor glycerophospholipids determines pro- or anti-apoptotic signaling in primary neurons.' (Ryan SD et al., 2008).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with Platelet activating factor

Download all related citations
Per page 10 20 50 100 | Total 8526
Authors Title Published Journal PubMed Link
Moon DG et al. Platelet modulation of neutrophil superoxide anion production. 1990 Thromb. Haemost. pmid:2160133
Steen VM et al. The platelet-stimulating effect of adrenaline through alpha 2-adrenergic receptors requires simultaneous activation by a true stimulatory platelet agonist. Evidence that adrenaline per se does not induce human platelet activation in vitro. 1993 Thromb. Haemost. pmid:8259557
Iyú D et al. The role of prostanoid receptors in mediating the effects of PGE3 on human platelet function. 2012 Thromb. Haemost. pmid:22318645
Murakami K et al. A novel platelet activating factor antagonist, SM-12502, attenuates endotoxin-induced disseminated intravascular coagulation and acute pulmonary vascular injury by inhibiting TNF production in rats. 1996 Thromb. Haemost. pmid:8822594
Koyama M et al. Surface coverage of vascular grafts with cultured human endothelial cells from subcutaneous fat tissue obtained with a biopsy needle. 1996 Thromb. Haemost. pmid:8903004
van Giezen JJ et al. Fibrinolytic activity in blood is distributed over a cellular and the plasma fraction which can be modulated separately. 1994 Thromb. Haemost. pmid:7740459
Rezaul K et al. Protein-tyrosine kinase p72syk is activated by platelet activating factor in platelets. 1994 Thromb. Haemost. pmid:7740467
Handley DA et al. Evaluation of dose and route effects of platelet activating factor-induced extravasation in the guinea pig. 1984 Thromb. Haemost. pmid:6495262
Powling MJ and Hardisty RM Potentiation by adrenaline of Ca2+ influx and mobilization in stimulated human platelets: dissociation from thromboxane generation and aggregation. 1988 Thromb. Haemost. pmid:3388294
Montrucchio G et al. Mechanisms of the priming effect of low doses of lipopoly-saccharides on leukocyte-dependent platelet aggregation in whole blood. 2003 Thromb. Haemost. pmid:14597983
Prescott SM et al. The role of platelet-activating factor in endothelial cells. 1990 Thromb. Haemost. pmid:2274933
Le Blanc K et al. Impaired platelet binding of fibrinogen due to a lower number of GPIIB/IIIA receptors in polycythemia vera. 1998 Thromb. Res. pmid:9772010
Alam I et al. Human and rabbit platelets form platelet-activating factor in response to calcium ionophore. 1983 Thromb. Res. pmid:6407140
Bush LR and Smith SG Antagonism of U46619-induced aggregation of human and canine platelets by four TXA2 receptor antagonists. 1986 Thromb. Res. pmid:2948294
Belch JJ et al. Whole blood white cell aggregation: a novel technique. 1987 Thromb. Res. pmid:2448894
Ostermann G et al. Studies on the stimulation of human blood platelets by semi-synthetic platelet-activating factor. 1983 Thromb. Res. pmid:6408754
Nguyên P et al. Mechanisms of the platelet aggregation induced by activated neutrophils and inhibitory effect of specific PAF receptor antagonists. 1995 Thromb. Res. pmid:7778064
Namm DH and High JA Thrombin-induced formation of a polar lipid material within platelets that possesses platelet-activating activity. 1980 Thromb. Res. pmid:7209881
Shukla SD et al. Hypersensitivity of diabetic human platelets to platelet activating factor. 1992 Thromb. Res. pmid:1329254
Tsien WH et al. Variable responses of human platelets to synthetic platelet activating factor and their modification by epinephrine. 1982 Thromb. Res. pmid:7164038
Valone FH Inhibition of platelet-activating factor binding to human platelets by calcium channel blockers. 1987 Thromb. Res. pmid:3590086
Tokumura A et al. Platelet aggregation induced by ether-linked phospholipids. 2. Mechanism of desensitization of rabbit platelets by platelet activating factor and reversibility of inhibitory actions of its antagonists. 1987 Thromb. Res. pmid:3590110
Kloprogge E et al. Properties of PAF-acether-induced platelet aggregation and secretion. Studies in gel-filtered human platelets. 1983 Thromb. Res. pmid:6222507
Wade PJ et al. Effect of calcium and calcium antagonists on [3H]-Paf-acether binding to washed human platelets. 1986 Thromb. Res. pmid:3961730
Karlsson H et al. Heparin ameliorates pulmonary hypertension induced by platelet-activating factor in pigs. 1998 Thromb. Res. pmid:9694244
Cox CP and Wood KL Selective antagonism of platelet-activating factor (PAF)-induced aggregation and secretion in washed rabbit platelets by CV-3988, L-652731, triazolam and alprazolam. 1987 Thromb. Res. pmid:3629553
Catalán RE et al. Dissociation between secretion and protein phosphorylation in agonist-stimulated platelets; action of PCA-4230, a new antithrombotic drug. 1994 Thromb. Res. pmid:7974386
Ostermann G et al. Plasma from atherosclerotic patients exerts an increased degradation of platelet-activating factor. 1987 Thromb. Res. pmid:3629555
Nishizawa EE and Della-Coletta AA The formation of a thrombin-like material (TLM) following stimulation of leukocytes. 1984 Thromb. Res. pmid:6484896
Glusa E et al. Verapamil is a potent inhibitor of 5-HT-induced platelet aggregation. 1989 Thromb. Res. pmid:2528843
Stahl GL et al. Protective effects of a specific platelet activating factor (PAF) antagonist, WEB 2086, in traumatic shock. 1989 Thromb. Res. pmid:2718150
Sloan IG and Firkin BG Impaired fibrinolysis in patients with thrombotic or haemostatic defects. 1989 Thromb. Res. pmid:2814943
Ostermann G et al. Cooperative effects of 1-O-alkyl-2-O-acetyl-sn-glycero-3-phosphocholine (PAF-acether) and exogenous arachidonic acid in stimulation of human blood platelets. 1984 Thromb. Res. pmid:6710440
Lalau Keraly C et al. Inhibition by ticlopidine of Paf-acether-induced in vitro aggregation of rabbit and human platelets. 1984 Thromb. Res. pmid:6740569
Bernat A and Herbert JM Effect of various drugs on adriamycin-enhanced venous thrombosis in the rat: importance of PAF. 1994 Thromb. Res. pmid:8073411
Pletscher A et al. LDL induced shape change reaction of platelets is not due to PAF. 1989 Thromb. Res. pmid:2609294
Cox CP Effects of CV-3988, an antagonist of platelet-activating factor (PAF), on washed rabbit platelets. 1986 Thromb. Res. pmid:2421432
Croft KD and Beilin LJ Platelet and neutrophil function and eicosanoid release in a subject with abetalipoproteinaemia. 1993 Thromb. Res. pmid:8385810
Joseph R et al. Platelet-activating factor and red blood cells. 1989 Thromb. Res. pmid:2734734
Ostermann G et al. Inhibition of PAF-induced human platelet responses by newly synthesized ether phospholipids. 1991 Thromb. Res. pmid:2028445
Joseph R et al. Endothelin-1 and human platelet activity. 1991 Thromb. Res. pmid:2028454
Garcia JG et al. Effect of platelet activating factor on leukocyte-endothelial cell interactions. 1988 Thromb. Res. pmid:2842887
Suzuki K et al. The influence of 2-mercaptoethanol on von Willebrand factor and bovine platelet aggregating factor. 1980 Feb 1-15 Thromb. Res. pmid:6966083
Küster LJ and Frölich JC PAF-induced platelet aggregation and TXB2 formation. 1989 Thromb. Res. pmid:2922704
Ostermann G et al. Stimulation and desensitization of human and rabbit platelets by 1-O-hexadecyl-2-O-methyl-rac-glycero-3-phosphocholine and analogues. 1986 Thromb. Res. pmid:3764811
Ishii H et al. A platelet aggregating substance contained in xanthine oxidase preparation from cow's milk. 1982 Thromb. Res. pmid:6897588
Neiman J et al. Platelet responses to platelet-activating factor are inhibited in alcoholics undergoing alcohol withdrawal. 1989 Thromb. Res. pmid:2617478
Csáki C et al. Role of platelet-activating factor in the development of endothelial dysfunction in hemorrhagic hypotension and retransfusion. 1992 Thromb. Res. pmid:1412179
May JA et al. Platelet responses to several agonists and combinations of agonists in whole blood: a placebo controlled comparison of the effects of a once daily dose of plain aspirin 300 mg, plain aspirin 75 mg and enteric coated aspirin 300 mg, in man. 1997 Thromb. Res. pmid:9361371
Lian EC et al. Purification and some properties of a protein obtained from normal human plasma which inhibits the platelet aggregation induced by thrombotic thrombocytopenic purpura plasma. 1984 Thromb. Res. pmid:6420930